{
    "info": {
        "nct_id": "NCT04598919",
        "official_title": "Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis",
        "inclusion_criteria": "1. IPF of any duration, confirmed or diagnosed by ILD center or expert according to Fleischner Guidelines (33). Subjects with a probable or indeterminant CT scan who otherwise meet the Fleischner criteria for IPF are eligible to be included in the study after a multidisciplinary evaluation. A positive Envisia genomic classifier score (34) on a lung biopsy specimen will be considered as strong evidence for a diagnosis of IPF. Subjects with a positive invisia genomic classifier score in conjunction with a probable or indeterminant CT scan are eligible to be included in the study after a multidisciplinary evaluation.\n2. Women or men >40 years of age at the time of screening\n3. FVC%>45% of predicted value (GLI-2012)\n4. Single breath DLCO% ≥ 30 - inclusive of predicted (without bronchodilator and uncorrected for hemoglobin GLI-2017)\n5. FEV1/FVC>70 (GLI-2012)\n6. Provision of signed/dated written informed consent prior to any study-specific procedures\n7. Females must be of nonchildbearing potential (defined as surgically sterilized [i.e., bilateral tubal ligation, bilateral oophorectomy or complete hysterectomy] or postmenopausal [defined as 12 months with no menses without an alternative medical cause] with a follicle-stimulating hormone [FSH] > 25.8 IU/L) or use a highly effective method of contraception (defined as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; progestogen only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo\n8. Male subjects must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo to prevent pregnancy in a partner. Male subjects must not donate or bank sperm for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo.\nHealthy volunteers allowed\nMust have minimum age of 40 Years",
        "exclusion_criteria": "1. Requirement for supplemental oxygen > 4 L/min at rest to maintain saturation > 90%\n2. Active infection at screening or randomization\n3. Known active or latent hepatitis B or C\n4. Life expectancy for disease other than IPF < 2.5 years (Investigator assessment)\n5. Listed for lung transplantation\n6. Taking pirfenidone or nintedanib in the last 4 weeks\n7. Pregnancy or lactation\n8. Known allergic reactions to components of saracatinib\n9. Treatment with another investigational drug or other intervention within 8 weeks\n10. Current smoker or tobacco use within 4 months\n11. Major surgery within the past 2 months\n12. Advanced hematologic, renal, hepatic, any lung disease determined by the investigator to be non-IPF related or metabolic disease that, in the opinion of the investigator, would make it unsafe for the person to receive study drug.\n13. Previous lung transplantation\n14. Inability to attend scheduled study visits\n15. Inability to give informed consent\n16. Inability to perform pulmonary function testing\n17. History of malignancy in the past two years, other than squamous or basal cell skin cancer\n18. Previous acute exacerbation of IPF requiring hospitalization and/or antibiotics within 90 days before the first dose of the investigational product\n19. Liver function test results ≥3× upper limit of normal (ULN) liver isoform of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) or ≥2×ULN total bilirubin (excepting documentation of benign hereditary cause). An isolated total bilirubin elevation (ie, no significant concomitant elevation in ALT or AST) at baseline of ≤ 2xULN is permitted. If there is concomitant elevation in ALT or AST to ≤3xULN, then the threshold for total bilirubin is ≤1.5xULN.\n20. Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula\n21. Known pulmonary hypertension (PH) requiring PH-specific treatment\n22. Chronic oral corticosteroids at doses greater than prednisone 10 mg/day (or equivalent)\n23. Refer to 6.5 Concomitant Therapy for exclusions based on co-medications",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2. Women or men >40 years of age at the time of screening",
            "criterions": [
                {
                    "exact_snippets": "Women or men >40 years of age at the time of screening",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": [
                                "female",
                                "male"
                            ]
                        },
                        {
                            "requirement_type": "age at screening",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Provision of signed/dated written informed consent prior to any study-specific procedures",
            "criterions": [
                {
                    "exact_snippets": "Provision of signed/dated written informed consent",
                    "criterion": "written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. FVC%>45% of predicted value (GLI-2012)",
            "criterions": [
                {
                    "exact_snippets": "FVC%>45% of predicted value (GLI-2012)",
                    "criterion": "forced vital capacity (FVC) percent predicted",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 45,
                                "unit": "% of predicted (GLI-2012)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 40 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 40 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Single breath DLCO% ≥ 30 - inclusive of predicted (without bronchodilator and uncorrected for hemoglobin GLI-2017)",
            "criterions": [
                {
                    "exact_snippets": "Single breath DLCO% ≥ 30 - inclusive of predicted (without bronchodilator and uncorrected for hemoglobin GLI-2017)",
                    "criterion": "single breath DLCO% (diffusing capacity of the lung for carbon monoxide)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "% of predicted"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": "single breath"
                        },
                        {
                            "requirement_type": "bronchodilator use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "hemoglobin correction",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "reference standard",
                            "expected_value": "GLI-2017"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. FEV1/FVC>70 (GLI-2012)",
            "criterions": [
                {
                    "exact_snippets": "FEV1/FVC>70 (GLI-2012)",
                    "criterion": "FEV1/FVC ratio",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 70,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "reference_standard",
                            "expected_value": "GLI-2012"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Females must be of nonchildbearing potential (defined as surgically sterilized [i.e., bilateral tubal ligation, bilateral oophorectomy or complete hysterectomy] or postmenopausal [defined as 12 months with no menses without an alternative medical cause] with a follicle-stimulating hormone [FSH] > 25.8 IU/L) or use a highly effective method of contraception (defined as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; progestogen only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo",
            "criterions": [
                {
                    "exact_snippets": "Females must be of nonchildbearing potential (defined as surgically sterilized [i.e., bilateral tubal ligation, bilateral oophorectomy or complete hysterectomy]",
                    "criterion": "female sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "sterilization procedure",
                            "expected_value": [
                                "bilateral tubal ligation",
                                "bilateral oophorectomy",
                                "complete hysterectomy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "postmenopausal [defined as 12 months with no menses without an alternative medical cause]",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "postmenopausal duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "absence of menses",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "alternative medical cause for amenorrhea",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "follicle-stimulating hormone [FSH] > 25.8 IU/L",
                    "criterion": "follicle-stimulating hormone (FSH) level",
                    "requirements": [
                        {
                            "requirement_type": "FSH level",
                            "expected_value": {
                                "operator": ">",
                                "value": 25.8,
                                "unit": "IU/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "use a highly effective method of contraception (defined as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; progestogen only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS)",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation",
                                "progestogen only hormonal contraception associated with inhibition of ovulation",
                                "intrauterine device (IUD)",
                                "intrauterine hormone-releasing system (IUS)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo",
                    "criterion": "contraception duration",
                    "requirements": [
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": "from consent through 3 months after last dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Male subjects must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo to prevent pregnancy in a partner. Male subjects must not donate or bank sperm for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo.",
            "criterions": [
                {
                    "exact_snippets": "Male subjects must be surgically sterile",
                    "criterion": "male surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "sterility_status",
                            "expected_value": "surgically sterile"
                        }
                    ]
                },
                {
                    "exact_snippets": "using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo to prevent pregnancy in a partner",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "method_type",
                            "expected_value": [
                                "barrier methods",
                                "spermicides"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from consent through 3 months after last dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "Male subjects must not donate or bank sperm for the duration of the study (from the time they sign consent) and for 3 months after the last dose of drug/matching placebo",
                    "criterion": "sperm donation or banking",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "not donate or bank sperm"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from consent through 3 months after last dose"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "16. Inability to perform pulmonary function testing",
            "criterions": [
                {
                    "exact_snippets": "Inability to perform pulmonary function testing",
                    "criterion": "pulmonary function testing",
                    "requirements": [
                        {
                            "requirement_type": "ability to perform",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Listed for lung transplantation",
            "criterions": [
                {
                    "exact_snippets": "Listed for lung transplantation",
                    "criterion": "lung transplantation listing status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "listed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Previous lung transplantation",
            "criterions": [
                {
                    "exact_snippets": "Previous lung transplantation",
                    "criterion": "lung transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Pregnancy or lactation",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "lactation",
                    "criterion": "lactation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Inability to give informed consent",
            "criterions": [
                {
                    "exact_snippets": "Inability to give informed consent",
                    "criterion": "ability to give informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "22. Chronic oral corticosteroids at doses greater than prednisone 10 mg/day (or equivalent)",
            "criterions": [
                {
                    "exact_snippets": "Chronic oral corticosteroids at doses greater than prednisone 10 mg/day (or equivalent)",
                    "criterion": "oral corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "chronic use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg/day prednisone or equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Active infection at screening or randomization",
            "criterions": [
                {
                    "exact_snippets": "Active infection at screening or randomization",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": [
                                "screening",
                                "randomization"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "20. Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance <30 mL/min calculated by Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Known allergic reactions to components of saracatinib",
            "criterions": [
                {
                    "exact_snippets": "Known allergic reactions to components of saracatinib",
                    "criterion": "allergic reactions to components of saracatinib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "23. Refer to 6.5 Concomitant Therapy for exclusions based on co-medications",
            "criterions": [
                {
                    "exact_snippets": "exclusions based on co-medications",
                    "criterion": "co-medications",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Inability to attend scheduled study visits",
            "criterions": [
                {
                    "exact_snippets": "Inability to attend scheduled study visits",
                    "criterion": "attendance at scheduled study visits",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. History of malignancy in the past two years, other than squamous or basal cell skin cancer",
            "criterions": [
                {
                    "exact_snippets": "History of malignancy in the past two years, other than squamous or basal cell skin cancer",
                    "criterion": "malignancy history",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "squamous cell skin cancer",
                                "basal cell skin cancer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Previous acute exacerbation of IPF requiring hospitalization and/or antibiotics within 90 days before the first dose of the investigational product",
            "criterions": [
                {
                    "exact_snippets": "Previous acute exacerbation of IPF requiring hospitalization ... within 90 days before the first dose of the investigational product",
                    "criterion": "acute exacerbation of IPF requiring hospitalization",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Previous acute exacerbation of IPF requiring ... antibiotics within 90 days before the first dose of the investigational product",
                    "criterion": "acute exacerbation of IPF requiring antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "21. Known pulmonary hypertension (PH) requiring PH-specific treatment",
            "criterions": [
                {
                    "exact_snippets": "Known pulmonary hypertension (PH)",
                    "criterion": "pulmonary hypertension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "known diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring PH-specific treatment",
                    "criterion": "PH-specific treatment",
                    "requirements": [
                        {
                            "requirement_type": "requirement for treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Current smoker or tobacco use within 4 months",
            "criterions": [
                {
                    "exact_snippets": "Current smoker",
                    "criterion": "smoking status",
                    "requirements": [
                        {
                            "requirement_type": "current smoker",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tobacco use within 4 months",
                    "criterion": "tobacco use within past 4 months",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Taking pirfenidone or nintedanib in the last 4 weeks",
            "criterions": [
                {
                    "exact_snippets": "Taking pirfenidone ... in the last 4 weeks",
                    "criterion": "pirfenidone use",
                    "requirements": [
                        {
                            "requirement_type": "use within last weeks",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Taking ... nintedanib in the last 4 weeks",
                    "criterion": "nintedanib use",
                    "requirements": [
                        {
                            "requirement_type": "use within last weeks",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Requirement for supplemental oxygen > 4 L/min at rest to maintain saturation > 90%",
            "criterions": [
                {
                    "exact_snippets": "Requirement for supplemental oxygen > 4 L/min at rest",
                    "criterion": "supplemental oxygen requirement at rest",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "L/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "to maintain saturation > 90%",
                    "criterion": "oxygen saturation",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Life expectancy for disease other than IPF < 2.5 years (Investigator assessment)",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy for disease other than IPF < 2.5 years",
                    "criterion": "life expectancy for disease other than IPF",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2.5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Treatment with another investigational drug or other intervention within 8 weeks",
            "criterions": [
                {
                    "exact_snippets": "Treatment with another investigational drug ... within 8 weeks",
                    "criterion": "treatment with another investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Treatment with ... other intervention within 8 weeks",
                    "criterion": "treatment with other intervention",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Major surgery within the past 2 months",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within the past 2 months",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Advanced hematologic, renal, hepatic, any lung disease determined by the investigator to be non-IPF related or metabolic disease that, in the opinion of the investigator, would make it unsafe for the person to receive study drug.",
            "criterions": [
                {
                    "exact_snippets": "Advanced hematologic, renal, hepatic, any lung disease determined by the investigator to be non-IPF related or metabolic disease ... would make it unsafe for the person to receive study drug",
                    "criterion": "advanced hematologic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety for study drug",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Advanced ... renal ... disease ... would make it unsafe for the person to receive study drug",
                    "criterion": "advanced renal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety for study drug",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Advanced ... hepatic ... disease ... would make it unsafe for the person to receive study drug",
                    "criterion": "advanced hepatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety for study drug",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any lung disease determined by the investigator to be non-IPF related ... would make it unsafe for the person to receive study drug",
                    "criterion": "non-IPF related lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety for study drug",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "metabolic disease ... would make it unsafe for the person to receive study drug",
                    "criterion": "metabolic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "safety for study drug",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "19. Liver function test results ≥3× upper limit of normal (ULN) liver isoform of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) or ≥2×ULN total bilirubin (excepting documentation of benign hereditary cause). An isolated total bilirubin elevation (ie, no significant concomitant elevation in ALT or AST) at baseline of ≤ 2xULN is permitted. If there is concomitant elevation in ALT or AST to ≤3xULN, then the threshold for total bilirubin is ≤1.5xULN.",
            "criterions": [
                {
                    "exact_snippets": "Liver function test results ≥3× upper limit of normal (ULN) liver isoform of aspartate aminotransferase (AST)",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Liver function test results ≥3× upper limit of normal (ULN) ... alanine aminotransferase (ALT)",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Liver function test results ≥3× upper limit of normal (ULN) ... gamma glutamyl transpeptidase (GGT)",
                    "criterion": "gamma glutamyl transpeptidase (GGT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Liver function test results ≥3× upper limit of normal (ULN) ... alkaline phosphatase (ALP)",
                    "criterion": "alkaline phosphatase (ALP)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≥2×ULN total bilirubin (excepting documentation of benign hereditary cause)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "benign hereditary cause"
                        }
                    ]
                },
                {
                    "exact_snippets": "An isolated total bilirubin elevation (ie, no significant concomitant elevation in ALT or AST) at baseline of ≤ 2xULN is permitted.",
                    "criterion": "total bilirubin (isolated, no significant concomitant elevation in ALT or AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "If there is concomitant elevation in ALT or AST to ≤3xULN, then the threshold for total bilirubin is ≤1.5xULN.",
                    "criterion": "total bilirubin (with concomitant ALT or AST elevation ≤3xULN)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "1. IPF of any duration, confirmed or diagnosed by ILD center or expert according to Fleischner Guidelines (33). Subjects with a probable or indeterminant CT scan who otherwise meet the Fleischner criteria for IPF are eligible to be included in the study after a multidisciplinary evaluation. A positive Envisia genomic classifier score (34) on a lung biopsy specimen will be considered as strong evidence for a diagnosis of IPF. Subjects with a positive invisia genomic classifier score in conjunction with a probable or indeterminant CT scan are eligible to be included in the study after a multidisciplinary evaluation.",
            "criterions": [
                {
                    "exact_snippets": "IPF of any duration, confirmed or diagnosed by ILD center or expert according to Fleischner Guidelines (33)",
                    "criterion": "idiopathic pulmonary fibrosis (IPF) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "confirmed or diagnosed by ILD center or expert according to Fleischner Guidelines"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "probable or indeterminant CT scan who otherwise meet the Fleischner criteria for IPF ... eligible to be included in the study after a multidisciplinary evaluation",
                    "criterion": "CT scan result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": [
                                "probable",
                                "indeterminant"
                            ]
                        },
                        {
                            "requirement_type": "meets_Fleischner_criteria",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "multidisciplinary_evaluation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "positive Envisia genomic classifier score (34) on a lung biopsy specimen ... considered as strong evidence for a diagnosis of IPF",
                    "criterion": "Envisia genomic classifier score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "specimen_type",
                            "expected_value": "lung biopsy"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive Envisia genomic classifier score in conjunction with a probable or indeterminant CT scan ... eligible to be included in the study after a multidisciplinary evaluation",
                    "criterion": "combined Envisia genomic classifier score and CT scan result",
                    "requirements": [
                        {
                            "requirement_type": "Envisia_score",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "CT_scan_result",
                            "expected_value": [
                                "probable",
                                "indeterminant"
                            ]
                        },
                        {
                            "requirement_type": "multidisciplinary_evaluation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "3. Known active or latent hepatitis B or C",
            "criterions": [
                {
                    "exact_snippets": "Known active or latent hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "latent"
                            ]
                        },
                        {
                            "requirement_type": "knowledge",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active or latent hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "latent"
                            ]
                        },
                        {
                            "requirement_type": "knowledge",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}